APA (7th ed.) Citation

(2020). The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

Chicago Style (17th ed.) Citation

The Janus Kinase 1/2 Inhibitor Ruxolitinib in COVID-19 with Severe Systemic Hyperinflammation. 2020.

MLA (8th ed.) Citation

The Janus Kinase 1/2 Inhibitor Ruxolitinib in COVID-19 with Severe Systemic Hyperinflammation. 2020.

Warning: These citations may not always be 100% accurate.